• Teva won FDA clearance for DEGEVMA (denosumab-adet), a biosimilar to Amgen’s Xgeva.
• Label covers Xgeva’s full uses, including prevention of bone complications in advanced cancer with bone metastases.
• Approval follows March 2026 FDA clearance of PONLIMSI, giving Teva a U.S. denosumab biosimilar portfolio across Xgeva, Prolia.
• U.S. launches for DEGEVMA, PONLIMSI expected in coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609281600PRIMZONEFULLFEED1001275047) on September 28, 2026, and is solely responsible for the information contained therein.